Literature DB >> 14559800

Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.

Dharminder Chauhan1, Guilan Li, Reshma Shringarpure, Klaus Podar, Yasuyuki Ohtake, Teru Hideshima, Kenneth C Anderson.   

Abstract

Bortezomib (PS-341), a selective inhibitor of proteasome, induces apoptosis in various tumor cells, but its mechanism of action is unclear. Treatment with PS-341 induces apoptosis in SUDHL6 (DHL6), but not SUDHL4 (DHL4), lymphoma cells. Microarray analysis shows high RNA levels of heat shock protein-27 (Hsp27) in DHL4 versus DHL6 cells, which correlates with Hsp27 protein expression. Blocking Hsp27 using an antisense strategy restores the apoptotic response to PS-341 in DHL4 cells; conversely, ectopic expression of wild-type Hsp27 renders PS-341-sensitive DHL6 cells resistant to PS-341. These findings provide the first evidence that Hsp27 confers PS-341 resistance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14559800

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

Review 1.  Mantle cell lymphoma: evolving novel options.

Authors:  Andre Goy
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

2.  Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A.

Authors:  Andrew J Kale; Ryan P McGlinchey; Anna Lechner; Bradley S Moore
Journal:  ACS Chem Biol       Date:  2011-09-26       Impact factor: 5.100

3.  Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.

Authors:  Claire Fabre; Naoya Mimura; Kathryn Bobb; Sun-Young Kong; Güllü Gorgun; Diana Cirstea; Yiguo Hu; Jiro Minami; Hiroto Ohguchi; Jie Zhang; Jeffrey Meshulam; Ruben D Carrasco; Yu-Tzu Tai; Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2012-07-17       Impact factor: 12.531

4.  Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.

Authors:  M A Frassanito; K De Veirman; V Desantis; L Di Marzo; D Vergara; S Ruggieri; T Annese; B Nico; E Menu; I Catacchio; R Ria; V Racanelli; M Maffia; E Angelucci; D Derudas; R Fumarulo; F Dammacco; D Ribatti; K Vanderkerken; A Vacca
Journal:  Leukemia       Date:  2015-10-21       Impact factor: 11.528

5.  The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.

Authors:  Kenneth C Anderson
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

6.  Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myeloma.

Authors:  Lingjuan Huang; Yanmeng Wang; Ju Bai; Yun Yang; Fangxia Wang; Yuandong Feng; Ru Zhang; Fangmei Li; Peihua Zhang; Nan Lv; Lei Lei; Jinsong Hu; Aili He
Journal:  Cell Stress Chaperones       Date:  2020-02-06       Impact factor: 3.667

7.  Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis.

Authors:  Morgan O'Hayre; Catherina L Salanga; Thomas J Kipps; Davorka Messmer; Pieter C Dorrestein; Tracy M Handel
Journal:  PLoS One       Date:  2010-07-22       Impact factor: 3.240

8.  Characterization of bortezomib-adapted I-45 mesothelioma cells.

Authors:  Lidong Zhang; James E Littlejohn; Yu Cui; Xiaobo Cao; Chander Peddaboina; W Roy Smythe
Journal:  Mol Cancer       Date:  2010-05-18       Impact factor: 27.401

9.  Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.

Authors:  Callum M Sloss; Fang Wang; Rong Liu; Lijun Xia; Michael Houston; David Ljungman; Michael A Palladino; James C Cusack
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

10.  A novel combination treatment for breast cancer cells involving BAPTA-AM and proteasome inhibitor bortezomib.

Authors:  Azmi Yerlikaya; Elif Erdoğan; Emrah Okur; Şerife Yerlikaya; Bircan Savran
Journal:  Oncol Lett       Date:  2016-05-17       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.